New FDA Approval for Pfizer's BOSULIF® (BOSUTINIB)
On December 19, 2017, the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) to expand the indication for BOSULIF® (bosutinib) to include adult patients with newly-diagnosed chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML).
Pfizer Press Release:
Prescribing information:
http://labeling.pfizer.com/ShowLabeling.aspx?id=884